Evaluation of a First-in-Class Proteasome Inhibitor in Patients With Moderate to Severe Rosacea

CONCLUSION: This study demonstrates that topical ACU-D1 is safe and well-tolerated by patients in the study and demonstrates efficacy in reducing inflammatory lesions and erythema in patients with rosacea. Improvement was also noted on Canfield imaging, and this modality is likely to be used as an objective measure in the future. Further studies are warranted based on these initial positive results. ClinicalTrials.gov Identifier: NCT03064438 J Drugs Dermatol. 2021;20(6):660-664. doi:10.36849/JDD.5925.PMID:34076401 | DOI:10.36849/JDD.2021.5925

Source: Journal of Drugs in Dermatology - June 2, 2021 Category: Dermatology Authors: J Mark Jackson Rick Coulon Jack L Arbiser Source Type: research